HIF2 Regulates Intestinal Wnt5a Expression

Carolina J. García García1,2,3,4, Ariana C. Acevedo Díaz5, Neeraj Kuman2,3, Suman Govindaraju3, Marimar de la Cruz Bonilla1,3,4, F. Anthony San Lucas6, Nicholas D. Nguyen2,3, Iancarlos Jiménez Sacarello4, Helen Piwnica-Worms3, Anirban Maitra6 and Cullen M. Taniguchi2,3*

1 The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, United States, 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4 School of Medicine, University of Puerto Rico, Rio Piedras, PR, United States, 5 Department of Biology, University of Puerto Rico, Bayamón, PR, United States, 6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Radiation therapy for abdominal tumors is challenging because the small intestine is exquisitely radiosensitive. Unfortunately, there are no FDA-approved therapies to prevent or mitigate GI radiotoxicity. The EGLN protein family are oxygen sensors that regulate cell survival and metabolism through the degradation of hypoxia-inducible factors (HIFs). Our group has previously shown that stabilization of HIF2 through genetic deletion or pharmacologic inhibition of the EGLNs mitigates and protects against GI radiotoxicity in mice by improving intestinal crypt stem cell survival. Here we aimed to elucidate the molecular mechanisms by which HIF2 confers GI radioprotection. We developed duodenal organoids from mice, transiently overexpressed non-degradable HIF2, and performed bulk RNA sequencing. Interestingly, HIF2 upregulated known radiation modulators and genes involved in GI homeostasis, including Wnt5a. Non-canonical Wnt5a signaling has been shown by other groups to improve intestinal crypt regeneration in response to injury. Here we show that HIF2 drives Wnt5a expression in multiple duodenal organoid models. Luciferase reporter assays performed in human cells showed that HIF2 directly activates the WNT5A promoter via a hypoxia response element. We then evaluated crypt regeneration using spheroid formation assays. Duodenal organoids that were pre-treated with recombinant Wnt5a had a higher cryptogenic capacity after irradiation, compared to vehicle-treated organoids. Conversely, we found that Wnt5a knockout decreased the cryptogenic potential of intestinal stem cells following irradiation. Treatment with recombinant Wnt5a prior to irradiation rescued the cryptogenic capacity of Wnt5a knockout organoids, indicating that Wnt5a is necessary and sufficient for duodenal radioprotection. Taken together, our results suggest that HIF2 radioprotects the GI tract by inducing Wnt5a expression.

Keywords: radiotherapy, intestinal stem cells, GI radiotoxicity, hypoxia, HIF2, Wnt5a
INTRODUCTION

Radiation is one of the four pillars of cancer care, with approximately half of cancer patients receiving radiotherapy at some point of their treatment regimen (1). Similar to chemotherapy, the efficacy of radiotherapy is limited by normal tissue toxicity. This toxicity is especially limiting in the case of abdominal and pelvic cancers, which are surrounded by the exquisitely radiosensitive gastrointestinal (GI) tract, and they require high doses of radiation to achieve tumoricidal effects (2). Multiple studies have highlighted how common GI radiotoxicity is among cancer patients (3–5). Results from a Phase 3 clinical trial showed that over a third of patients treated with 45 Gy or 50.4 Gy four-field pelvic radiotherapy or pelvic intensity-modulated radiotherapy reported GI symptoms following radiation treatment (6). Consequently, abdominal radiotherapy for cancers of the hepatobiliary tract and pancreas are administered at sub-curative doses to avoid GI radiotoxicity. Recent clinical trials have shown that dose-escalated radiotherapy using highly precise 3D conformal radiation techniques, such as stereotactic body radiotherapy and intensity-modulated radiotherapy, can improve outcomes (7–9), but these techniques still cannot avoid the small intestines (10). Furthermore, these sophisticated techniques are not widely accessible, as they require specialized expertise that is limited to some academic centers. Thus, an alternative to reduce GI radiotoxicity in cancer patients is to use a radioprotector to prevent radiation-induced damage and/or to improve GI repair following radiotherapy (9).

There are currently no FDA-approved radioprotectors of the GI tract. The intestine has a physiological hypoxia gradient that arises due to its vascular anatomy, and the hypoxia-inducible factors (HIFs) regulate various genes required for intestinal barrier function (11). The HIFs are transcription factors which are hydroxylated by the EGLN family of prolyl hydroxylases in the presence of oxygen, iron, and 2-oxoglutarate, allowing the von Hippel-Lindau E3 ubiquitin ligase complex to bind and tag HIFs for proteosomal degradation (12–19). The stabilization of HIFs through hypoxia or EGLN inhibition allows them to regulate cell metabolism and survival (12), induce tissue remodeling (20), increase epithelial integrity (21), and promote stem cell survival (13). There are two main HIF isoforms: HIF1 and HIF2. Our group has previously shown that stabilization of HIF2, but not HIF1, significantly reduces GI radiotoxicity without sparing hypoxic pancreatic tumors (22, 23). However, the mechanisms by which HIF2 confers radioprotection to the small intestine remain unclear.

In the current study, we generated a 3D murine small intestinal organoid model system (24), transiently overexpressed a non-degradable HIF2 allele (25), and performed whole transcriptomic analysis to gain insight in this regard. We found that HIF2 directly induces Wnt5a expression, a non-canonical Wnt family glycoprotein, in both murine and human cell lines, by activating its promoter. Like other Wnt family members, Wnt5a plays an important role in the in the embryonic development and subsequent homeostasis GI tract, and enhances regeneration following injury (26, 27). Here, we show that Wnt5a is necessary for small intestinal crypt regeneration following radiation and that addition of exogenous Wnt5a to duodenal 3D organoid cultures improves their cryptogenic capacity. Together, our data indicate that HIF2 radioprotecs the small intestine, at least in part, by inducing Wnt5a expression.

MATERIALS AND METHODS

Cell Lines and Reagents

L-WRN cells were obtained from the ATCC (CRL-3276). HEK293-derived Adherent-293 (AD-293) cells were obtained from Stratagene (240085). CBRLuc-mCherry reporter murine duodenal organoids were a gift from Dr. Helen Piwnica-Worms (28). Murine duodenal organoids were cultured at 37°C in 5% CO2 and 5% O2, while all other cell lines were cultured at 37°C in standard 5% CO2 incubators. All cell lines were authenticated by short tandem repeat profiling and were confirmed to be Mycoplasma free. Recombinant human/mouse Wnt5a was purchased from R&D Biosysystems (645-WN-010-CF).

Mice

All experimental mouse work adhered to the standards articulated in the Animal Research: Reporting of In Vivo Experiments guidelines. Additionally, all mouse work was approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center. Mice were maintained on a 12-hour light/dark cycle and were provided with sterilized water and standard rodent chow (Prolab Isopro RMH 3000 irradiated feed) ad libitum. C57BL/6 mice (RRID: IMSR_JAX:000664), Wnt5a+/− mice (RRID: IMSR_JAX:026626) (29), and R26-LSL-hHIF2aDPA mice (RRID: IMSR_JAX:009674) (25) were obtained from Jackson Laboratories.

Generation of 3D Small Intestinal Organoids

L-WRN conditioned media was prepared as previously described (24, 28). Briefly, L-WRN cells were maintained in DMEM high glucose media (Sigma, D6429) supplemented with 10% (v/v) FBS (Sigma, F4135, 1% (v/v) Penicillin/Streptomycin (Sigma, P4333), 500 µg/ml Hygromycin B Gold (In vivoGen, anti-hg-1), and 500 µg/ml G418 (Sigma, G8168). Once cells were confluent, the media was replaced with Advanced DMEM/F12 media (Gibco, 12634010) supplemented with 10% (v/v) FBS, 1% (v/v) Penicillin/Streptomycin, and 2 mM L-glutamine (Sigma, G7513). Conditioned media was collected for six days, centrifuged at 3,000 rpm for 5 minutes, vacuum filtered through a 20 µM PES membrane (Thermo Scientific, 567-0020), and stored at −80°C.

Duodenal crypts were isolated from C57BL/6 mice, R26-LSL-hHIF2aDPA mice, and Wnt5a+/− mice, and 3D organoid cultures were established as previously described (24, 28). For all steps in this protocol, EDTA (Sigma-Aldrich, E7889) was added fresh to both PBS (Cytiva, SH30256.LS) and HBSS without calcium and magnesium (Gibco, 14025092) to a final concentration of 2 mM,
and kept on ice. Mice were humanely euthanized by CO₂ inhalation followed by cervical dislocation. The duodenum was measured 1 cm below the pylorus, and 4 cm were resected and flushed with PBS/EDTA, then incubated on fresh PBS/EDTA for 10 min on ice, and finally transferred to ice-cold HBSS/EDTA. Duodenal samples were then serially vortexed at 1,600 rpm at 4°C, in fresh HBSS each time, for 5 min, 3 min, and 8 min. Supernatants from the second and third vortexes were combined and passed through 70-µm strainers (Corning, 431751) to isolate crypts and remove any villi that might remain after the washes. Duodenal crypts were pelleted at 1,000 rpm at 4°C, then washed in Advanced DMEM/F12 supplemented with 10% (v/v) FBS, 1% (v/v) Penicillin/Streptomycin, and 2 mM L-glutamine, and re-centrifuged as before. The pelleted crypts were resuspended in 50% (v/v) Matrigel (Corning, 354234) diluted with the crypt washing media, and then were seeded as domes into 24-well plates (Corning, 3524).

After Matrigel solidification at 37°C, the duodenal organoids were cultured in 50% (v/v) L-WRN conditioned media supplemented with 10 mM Y27632 (ROCK inhibitor; Sigma-Aldrich, Y0503) and 10 µM SB431542 (TGF-β RI Kinase Inhibitor VI; Sigma-Aldrich, 616461). The culture media was refreshed every other day and the organoids were passed every third day.

**Adenviral Transduction**

Ad-GFP (VVC-U of Iowa-4, Ad5CMVGFp), Ad-Cre (VVC-U of Iowa-5, Ad5CMVCre), and Ad-Cre-GFP (VVC-U of Iowa-1174, Ad5CMVCre-GFP) viral vectors were provided by the University of Iowa Viral Vector Core (http://www.medicine.uiowa.edu/vectcore). Ad-human HIF1 and Ad-human HIF2 viral vectors were previously produced (30) using hHIF1 (Addgene #18955) and hHIF2 plasmids (Addgene #18956) that contain double proline-to-alanine substitutions which render them nondegradable by VHL (31). Duodenal organoids were transduced after at least three passages. First, organoids were harvested by incubation with Cell Recovery Solution (Corning, 352235). Single ISCs were stained with Trypan Blue (Bio-Rad, 1620215) using a Trans-Blot Turbo transfer system (Bio-Rad). After blocking with 5% (w/v) skim milk powder (Bio-Rad, 37536) at 4°C, 1 µg/mL anti-β-actin rabbit (Cell Signaling Technology, 4970S) was used at 1:1,000. The membrane was then washed and incubated with HRP-conjugated secondary antibody for 1h. The membrane was developed with Clarity Western ECL Substrate kit (Bio-Rad, 1705061) and visualized using a ChemiDoc imaging system (Bio-Rad). Relative protein expression was quantified based on band intensity using ImageJ software (RRID : SCR_003070) and normalized to control group.

**Western Blotting**

Duodenal organoids were released from Matrigel by incubation with Cell Recovery Solution for 30 min on ice, then centrifugation at 1,000 rpm for 5 min at 4°C, followed by washing with cold PBS. Organoids were then lysed in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific, 78501) supplemented with protease inhibitor (Roche Life Science, 11836170001) and phosphatase inhibitor (Roche Life Science, 4906837001), and then denatured with 4x Laemmli sample buffer (Bio-Rad, 1610747). Equal cell protein lysate amounts were resolved on SDS-PAGE gel (Bio-Rad, 4568034) and transferred onto a nitrocellulose membrane (Bio-Rad, 1620215) using a Trans-Blot Turbo transfer system (Bio-Rad). After blocking with 5% (w/v) skim milk powder (Bio-Rad, 170640XTU) in TBS-T for 1h at room temperature, the membrane was probed with primary antibodies diluted in Superblock T20 (ThermoFisher Scientific, 37536) at 4°C overnight. Anti-HIF2α rabbit (Novus Biologicals, NB100-122) was used at 1:500 and anti-β-actin rabbit (Cell Signaling Technology, 4970S) was used at 1:1,000. The membrane was then washed and incubated with HRP-conjugated secondary antibody for 1h. The membrane was developed with Clarity Western ECL Substrate kit (Bio-Rad, 1705061) and visualized using a ChemiDoc imaging system (Bio-Rad). Relative protein expression was quantified based on band intensity using ImageJ software (RRID : SCR_003070) and normalized to control group.

**RNA Purification and Quantitative Real Time-PCR Analysis**

Duodenal organoids were released from Matrigel as indicated above, then homogenized by vortexing and vigorously pipetting, and then RNA was purified using an RNeasy mini kit following the manufacturer’s handbook (Qiagen, 74106). Reverse transcription was performed with a mix of random primers and oligos using an iScript cDNA Synthesis kit (Bio-Rad, 17089891). Next, qRT-PCR was performed using SYBR Green Master mix (Bio-Rad, 1725124) and the primer assays listed on Supplementary Table 1, on a CFX384 Real-time system (Bio-Rad). Relative gene expression and fold change was calculated using Hprt and Tbp as reference genes.

**RNA Sequencing and Analysis**

Duodenal organoids from C57BL/6 mice transduced with either Ad-GFP, Ad-hHIF1, or Ad-hHIF2 were harvested and RNA was purified using an RNeasy mini kit. RNA purity and concentration were measured using an Epoch Microplate Spectrophotometer with a Take3 Micro-Volume Plate, and Gen5 software (v2), all from BioTek Instruments, Inc. Library preparation and sequencing were performed in the Sequencing and Microarray Facility at MD Anderson Cancer Center. The raw sequencing data was downloaded from the core server and low-quality reads were removed and Q20 and GC contents were calculated. Transcript abundance was quantified using the RSEM software package (RRID : SCR_013027) (32). Differential
expression analysis was performed using EBSeq software package (RRID: SCR_003526) (33). Supplementary Tables 2 and 3 show the output differential expression matrix for Ad-HIF2 and Ad-HIF1, respectively, compared to Ad-GFP.

**WNT5A Promoter Analysis and Dual Luciferase Assays**

The human WNT5a promoter from −2000 to +200 nucleotides from the +1 transcriptional start site (34) was synthesized directly into the KpnI- and XhoI-flanked region of the pUC57 vector (Genscript, SD1176). All mutant promoters were synthesized in a similar fashion. The specific sequences of the mutations can be found in Supplementary Figure 2. The KpnI- and XhoI-flanked fragments of each of the promoter constructs were excised and then ligated into the compatible BglII- and HindIII-flanked sites in the pGL4.10[Luc2] vector (Promega, E6651). AD-293 cells were cultured in DMEM supplemented with 10% FBS and 2 mM L-Glutamine. Cells were transfected using Xfect Transfection Reagent (TakaraBio, 631318) using the manufacturer’s standard protocol. For instance, a 96-well opaque plate was seeded with 9.5 x 10³ cells/well and transfected with 10 ng of hHIF1 plasmid, hHIF2 plasmid, or control GFP plasmid (Addgene #26822), 0.09 ng of WNT5A-luciferase construct, and 9 ng of Renilla luciferase, along with Xfect polymer. The transfected cells were incubated for 48 h in Opti-MEM media (Gibco, 31985070). Dual luciferase assays were performed using the Dual-Glo® Reagent (Promega, E2940) kit according to manufacturer’s instructions. The luminescence data was measured on a Cytation 3 luminometer (Biotek Instruments, Inc.). Luciferase signal was normalized to Renilla signal, and then WNT5A promoter transactivation was calculated as a fold change over control GFP plasmid transfection.

**Spheroid Formation Assays**

Spheroid Formation Assays were performed as previously described (28), using a murine duodenal Click Beetle Red Luciferase-mCherry (CBRLuc-mCherry) reporter organoid line and Wnt5a-null duodenal organoids. Briefly, duodenal organoid cultures were exposed to the indicated pre-radiation treatments and then irradiated using an X-Rad 320 cell irradiator (Precision X-Ray). Immediately after irradiation, the duodenal organoids were harvested using Cell Recovery Solution and then digested into single ISCs using TrypLE supplemented with Y27632 and N-Acetylcysteine, followed by filtering through a cell strainer as detailed above for Adenoviral Transduction. Live cells were quantified using ViaStain™ AO/PI Staining Solution (Nexcelom, CS2-0106) in a Cellometer® Vision CBA Image Cytometer (Nexcelom). Live duodenal ISCs were seeded in Matrigel in 24-well culture plates at a density of 5,000 cells/well. Organoids were maintained in 50% L-WRN conditioned media supplemented with 10 µM Y27632 and 10 µM SB431542 for six days, then surviving cells were assessed via bioluminescence or z-stack imaging. For quantification of bioluminescence, organoids were incubated with 300 µg/ml of D-Luciferin Firefly (Gold Biotechnology, L-123) in the media for 20 min at 37°C, and measurements were taken using a CLARIOstar plate reader (BMG Labtech). Sample wells were first normalized to blank Matrigel wells, and then to unirradiated controls. Z-stack images covering the entire Matrigel dome area were taken using a Cytation 3 Cell Imaging Multi-Mode Reader (Biotek Instruments, Inc.). Z-stack images were stitched using Photoshop version 19.1.7 (RRID: SCR_014199) and viable organoids measuring at least 150 µm were manually quantified using ImageJ version 1.52q (RRID: SCR_003070). For organoids analyzed via z-stack imaging, the surviving fraction was calculated as described previously (35).

**RESULTS**

**Transcriptomic Analysis of HIF2 Overexpression in Small Intestinal Organoids by RNA Sequencing**

To gain insight into how the HIFs regulate GI biology and to understand the mechanisms by which HIF2 confers radioprotection to the small intestine, we generated a 3D murine small intestinal organoid model system. We harvested duodenal crypts of wild-type C57BL/6 mice, seeded them in basement membrane matrix (Matrigel), and cultured them in conditioned media containing Wnt3a, R-spondin 3, and noggin (Figure 1A) (24). These conditions enrich for intestinal stem cells (ISCs), which self-assemble into crypt-like 3D structures that are able to recapitate the small intestinal crypt ex vivo (36). We then transiently overexpressed a non-degradable HIF1 or HIF2 allele (25), which contain mutations in the two key prolyl residues that are hydroxylated by the EGLN proteins, rendering them stable even under normoxic conditions, using adenoviral particles (Figure 1A). We confirmed adenoviral-mediated HIF overexpression by both western blot and qRT-PCR, and then performed RNA sequencing (Figures 1A–C).

Among thousands of coding transcripts assessed, 1,113 genes exhibited significant differential expression between control GFP- and HIF2-overexpressing duodenal organoids (Figure 2A and Supplementary Table 2). All the differentially expressed genes with statistical significance were selected with p < 0.05, False Discovery Rate (FDR) < 0.05, and at least 2-fold change. Hierarchical clustering analysis revealed a total of 461 upregulated genes and 652 downregulated genes (Supplementary Table 2). The entire set of differentially expressed genes can be visualized in a volcano plot in Figure 2B. To validate our RNA sequencing results, we independently assessed the expression of 5 genes by qRT-PCR. Our results confirmed that Stat6, Aqp8, and Nos2 were upregulated and that Wnt4 and Egr1 were downregulated in HIF2-overexpressing duodenal organoids compared to wild-type
duodenal organoids, indicating that the RNA sequencing dataset is reliable (Figure 2C).

We also examined the transcriptome of HIF1-overexpressing organoids to gain more insight into how the HIFs regulate overall ISC biology. Among the thousands of coding transcripts assessed, only 55 genes exhibited significant differential expression between control GFP- and HIF1-overexpressing duodenal organoids, in which 25 genes were upregulated and 30 genes were downregulated (Supplementary Figure 1 and Supplementary Table 3). Interestingly, the only genes commonly upregulated by HIF1 and HIF2 in our dataset were Namp, Ppp1r3c, Rasgrf1, Klhl3, Mical2, and Nos2, and the only
transcripts commonly downregulated by both HIFs were Slc18a1, Gm37069, Hr, Gm12480, Gm13151, Gm21981, Klh30, Vcp-rs, Gm4204, AY512931, and Gm28037 (Supplementary Tables 2 and 3). We then focused our attention on the HIF2 dataset, as HIF2 and not HIF1, has been shown to be the main HIF isoform driving GI radioprotection (22).

**HIF2InducesIntestinalNon-CanonicalWnt5aExpression**

Interestingly, the HIF2-induced transcriptome included known radiation modulators as well as genes involved in GI healing and homeostasis, as highlighted in Figure 3A in blue and red, respectively. We identified Wnt5a as a transcriptional target of HIF2, but not HIF1 (Figure 3A and Supplementary Tables 2 and 3), and interestingly, Wnt5a has a known connection to non-canonical intestinal crypt regeneration (26). Thus, we took a candidate approach to further investigate its transcriptional regulation by HIF2. We verified that Wnt5a was upregulated by HIF2 using two approaches. First, we performed qRT-PCR to independently evaluate duodenal organoids that transiently overexpressed non-degradable HIF2 via Adeno-hHIF2 transduction (25), and found significantly increased Wnt5a expression by almost 50-fold compared to organoids transduced with Adeno-GFP (Figure 3B). Second, we generated duodenal organoids from mice that conditionally overexpressed non-degradable human HIF2 by knock-in into the Rosa 26 locus (R26-LSL-hHIF2) (25), transduced them with either Adeno-Cre or control Adeno-GFP vectors, and assessed Wnt5a expression using qRT-PCR. Stable HIF2 overexpression also resulted in significant upregulation of Wnt5a by 6-fold (Figure 3C). Together, these results suggest that HIF2 induces intestinal Wnt5a expression.

**HIF2DirectlyActivatestheWNT5APromoter**

The HIFs are transcription factors that recognize and bind hypoxia response elements (HREs) in promoter or enhancer regions to induce gene transcription (13). Thus, we analyzed the WNT5A promoter sequence to determine whether it contained putative HRE motifs and identified multiple low- and high-stringency HRE consensus sequences (Figure 4A and Supplemental Figure 2). To determine whether induction by HIF2 occurs directly or indirectly, we designed luciferase reporter constructs of the human WNT5A promoter spanning from 2,000 nucleotides upstream of the transcriptional start site (34) to 200 nucleotides downstream, containing five HRE consensus sequences that are closely associated with HIF ancillary sequences (HAS) and E-box motifs (Figure 4A and Supplemental Figure 2). HAS and E-box motifs are cis-element that are required for an HRE to be functionally active. Both motifs play a role in the recruitment of transcriptional machinery that together with HIF2 induce promoter activation (37–39). We transfected this construct into human embryonic kidney-derived Adherent 293 (AD-293) cells along with an expression vector

---

**FIGURE 3** | Candidate approach identifies Wnt5a as direct HIF2 target. (A) Post-Fold Change (PostFC) of 20 differentially expressed (DE) genes identified from the RNA sequencing analysis. (B) qRT-PCR validation of HIF2-induced Wnt5a upregulation in wild-type duodenal organoids infected with Ad-GFP or Ad-hHIF2. Data represents 3 biological replicates (3 technical replicates/mouse). (C) qRT-PCR showing HIF2-induced upregulation of Wnt5a in LSL-HIF2 duodenal organoids infected with Ad-GFP or Ad-Cre. Data represents 3 biological replicates (3 technical replicates/mouse). All error bars represent mean ± SEM. *P < 0.05, **P < 0.01, by Student’s t test.
encoding GFP or constitutively active human HIF1 or HIF2 (11) and performed dual luciferase reporter assays (25). We found that HIF2 significantly increased WNT5A promoter transactivation by eight-fold over GFP controls (Figure 4B). HIF1 only modestly affected promoter activity (Figure 4B).

To understand if any specific HRE motif of the WNT5A promoter is required for its activation by HIF2, we performed mutational analyses. We engineered transversion point mutations on the guanine and cytosine nucleotides of three distal and two proximal putative HRE sites within the promoter, and transfected AD-293 cells with these constructs to perform promoter activation studies (Figure 4C and Supplementary Figure 2). We found that independently mutating the two most distal HREs in the WNT5A promoter had the most impact on HIF2-induced transactivation, and that these two HREs are differentially regulated by HIF2. The point mutation at the HRE in position -1548 significantly diminished the previously observed HIF2-induced promoter activation, suggesting that the -1548HRE is necessary for HIF2’s ability to bind and positively regulate the WNT5A promoter (Figure 4C). Importantly, this -1548HRE resides upstream of a HAS, which is also in close proximity to an E-box (Figure 4A and Supplementary Figure 2). Conversely, mutating the -1648HRE resulted in an increased ability of HIF2 to transactivate the WNT5A promoter, suggesting that it might be a repressive HRE. Although the HRE at -1648 resides nearby E-box and HAS motifs, HRE sites that are preceded by cytosine nucleotides on 5' form E-box binding sites of other basic helix-loop-helix transcription factor families, and HIFs rarely recognize these (38). Moreover, while HIF2-induced gene upregulation is largely mediated by direct HIF2 binding to DNA motifs, HIF2-induced gene repression tends to occur indirectly through transcriptional co-repressors (37). Thus, we posit that direct binding of HIF2 to the -1548HRE promotes WNT5A transcription, whereas HIF2 interaction with the -1648HRE promotes the recruitment of repressive transcriptional machinery. The point mutations of the HREs at positions -631, -296, and +82 did not alter the activation of the WNT5A promoter by HIF2 (Figure 4C).
Taken all together, our results indicate that HIF2 directly activates the WNT5A promoter, possibly by binding the -1548HRE.

**Wnt5a Increases ISC Survival and Cryptogenic Potential Following Radiation**

Wnt5a is a non-canonical Wnt ligand that has been shown to promote the formation of new intestinal crypts in order to re-establish homeostasis after intestinal mucosal injury (26). To evaluate whether Wnt5a mediates HIF2-boosted GI radioprotection, we performed a spheroid formation assay, which is an ex vivo microcolony assay that allows us to evaluate potential radiation modifiers in small intestinal organoid cultures (28). We treated CBRLuc-mCherry, a murine duodenal mCherry reporter organoid line (28), with recombinant Wnt5a (rWnt5a) 10 hours prior to irradiation, then exposed them to 0-8 Gy of X-rays, and re-seeded single cells in Matrigel (Figures 5A, B). CBRLuc-mCherry organoids that were pre-treated with rWnt5a produced significantly higher relative bioluminescence levels six days after irradiation, compared to vehicle-treated organoids, indicating that rWnt5a increased the number of regenerating crypts (Figure 5B). Pre-treatment with rWnt5a significantly increased the cryptogenic capacity of CBRLuc-mCherry organoids exposed to 2 Gy and 4 Gy by 2-fold and 6-fold, respectively, and also increased the cryptogenic capacity of organoids exposed to 6 Gy by 2.8-fold, but this was not statistically significant (Figure 5B). Interestingly, CBRLuc-mCherry organoids that continued receiving rWnt5a treatment after irradiation did not display improved cryptogenic capacity (Supplementary Figure 3A). Moreover, initiating rWnt5a treatments only after irradiation also did not improve the cryptogenic capacity of CBRLuc-mCherry organoids (Supplementary Figure 3B). These results suggest that Wnt5a could be radioprotective to small intestinal crypts but does not mitigate radiation damage after it has occurred. A possible explanation for these results is that Wnt5a suppresses intestinal organoid proliferation by inducing TGF-β signaling (26), which would protect cycling ISCs from radiation, but would dampen their capacity to regenerate crypts if Wnt5a treatment was continued after the radiation injury was incited.

To understand whether Wnt5a is necessary for intestinal crypt regeneration following radiation injury, we generated conditional Wnt5a knockout (Wnt5a\(^{ CKO }\)) duodenal organoids from Wnt5a\(^{ flox }\) mice and transduced them with Adeno-Cre-GFP or control Adeno-GFP vectors. In agreement with published work demonstrating that Wnt5a is dispensable for homeostasis in the gut postnatally (40), deletion of Wnt5a did not affect organoid growth or morphology (Figure 5C). We then performed a modified spheroid formation assay using the Wnt5a\(^{ CKO }\) duodenal organoids and z-stack imaging, rather than bioluminescence, to quantify regenerating organoids (Figure 5D). Loss of Wnt5a did not affect the cryptogenic capacity of unirradiated duodenal organoids (Figure 5E and Supplementary Figure 4), again confirming that Wnt5a is dispensable for homeostasis (Figure 5C) (40). On the other hand, deletion of Wnt5a significantly reduced the fraction of surviving duodenal organoids after 6 Gy of radiation (Figure 5E and Supplementary Figure 4), indicating that Wnt5a is necessary for crypt regeneration following radiation. Furthermore, treatment with recombinant Wnt5a (rWnt5a) rescued Wnt5a-depleted duodenal organoids from radiation-induced ISC death (Figure 6). Taken together, these results suggest that Wnt5a increases ISC survival and is both necessary and sufficient for ISC radioprotection.

**DISCUSSION**

Radiation therapy for abdominal and pelvic tumors is challenging because the small intestine is exquisitely...
radiosensitive, which limits the dose that can be delivered to tumors without major GI toxicity (2–6). Unfortunately, there are no FDA-approved therapies to prevent GI radiotoxicities. Multiple groups, including our own, have shown that HIF2 stabilization by pharmacological EGLN inhibition protects the small intestine against radiation (22, 23, 41, 42). However, the mechanism by which HIF2 radioprotects ISC and prevents GI radiotoxicity remains unclear. The current study provides mechanistic insight into how HIF2 reduces the radiosensitivity of the intestinal crypt. Moreover, to the best of our knowledge, this is the first study that evidences a convergence between non-canonical Wnt signaling and hypoxia signaling.

Here we used ISC-enriched 3D duodenal organoid cultures to mimic the small intestinal crypt and studied the mechanism of HIF2 radioprotection by both transient and stable HIF2 overexpression. Unsurprisingly, the HIF2-induced intestinal transcriptome included many genes that are essential for normal GI homeostasis and barrier function, and interestingly, some of these genes have been implicated in cellular response to radiation. We took a candidate approach and focused our attention on Wnt5a, which has been shown to play roles in the development of the intestinal tract, the proliferation of ISCs, and their capacity to regenerate upon GI injury (26, 40, 43). In zebrafish embryos, Wnt5a has also been shown to regulate gastrulation and to ameliorate radiation-induced toxicity (43). Here we provide evidence that Wnt5a is a direct HIF2 target. We identified five major HRE sites within the human WNT5A promoter and our experiments in human cells confirmed that HIF2 directly activates the WNT5A promoter through a functional HRE motif located 1548 nucleotides upstream of the transcriptional start site. This -1548HRE site resides near HAS and E-box sequences, which help recruit transcriptional co-activators (38). Nevertheless, our promoter studies were focused on 2,2000 nucleotides surrounding the WNT5A transcriptional start site, thus, there could be additional distal HRE sites that are regulated by HIF2.

Our study is the first to show that Wnt5a could be a potential target to prevent GI radiotoxicity. We showed that Wnt5a is both necessary and sufficient for ISC survival and crypt regeneration after exposure to radiation. Deletion of Wnt5a completely impaired the ability of ISCs to form crypt spheres after being irradiated, and addition of rWnt5a rescued ISCs from radiation-induced cell death. Importantly, our phenotype was only reproducible when rWnt5a was administered before radiation.
treatments. Wnt5a signaling has been shown to inhibit both intestinal and hematopoietic stem cell proliferation (26, 44). Because radiation is more toxic to rapidly proliferating cells, suppression of cell proliferation prior to radiation would allow ISCs to sustain the effects of radiation. Wnt5a binds to the Frizzled (Fzd) family of cell surface receptors, including Fzd-1/2/4/5/7/8 (45), and its canonical co-receptors Lrp5/6 or its non-canonical co-receptors Ror1/2 and Ryk, and activates either the canonical Wnt/Beta-catenin pathway, the non-canonical planar cell polarity pathway, or the non-canonical Wnt/Ca2+ pathways (34). In intestinal organoids, non-canonical Wnt5a signaling through Ror2 induces TGF-β signaling and Smad3 phosphorylation with subsequent nuclear translocation, leading to increased expression of multiple cyclin-dependent kinase inhibitors, and ultimately arrest of cell proliferation (26). Thus, activation of these downstream signaling pathways could be a possible explanation for the relative success of Wnt5a as a radioprotector while failing to mitigate radiation injury post-exposure. It is important to note that our studies were limited to ex vivo duodenal organoid models and that our observations should be validated using in vivo GI radiation models.

Wnt5a has been implicated in tumor progression, raising concerns about its potential use as a GI radioprotective agent in cancer patients (46, 47). While this concern is warranted, HIF2 would only be activated for a short period only during radiation to reduce normal tissue toxicity, which may reduce the potential oncogenic effects of this molecule. Additional preclinical studies using cancer models to assess this relative risk are warranted before Wnt5a can be considered for clinical translation. Furthermore, we note that our radiation model employs conventional single fractions, whereas many GI radiation oncology regimens employ fractionated radiation. Accordingly, the extent of Wnt5a-afforded ISC radioprotection would need to be evaluated in the setting of fractionated regimens.

We note that HIF2 may have additional molecular mechanisms by which it promotes ISC survival and intestinal radioprotection. Prior studies have shown that HIF2 both protects and mitigates GI radiation injury (22), yet our results here suggest that Wnt5a does not mitigate intestinal crypt radiation injury. Thus, future studies should assess which HIF2 targets are potential GI radiation mitigators. For example, the Neuroepithelial cell transforming 1 (Net1) gene, which was significantly upregulated in our HIF2 dataset, has been shown to play a role in DNA damage repair after ionizing radiation (48, 49). Similarly, Ets1 and Klf4 are transcription factors that are essential for stem cell self-renewal and can regulate DNA damage repair (50, 51), and both were significantly upregulated by HIF2.

Moreover, our study was limited to the ISC compartment of the small intestine. However, other cellular compartments, such as the intestinal stromal niche, gut macrophages and the endothelial compartment have established roles in the intestinal response to injury (52, 53). Further investigation into these cellular compartments is required to fully dissect the role of HIF2 in the radiation responses of the intestinal tract.

**DATA AVAILABILITY STATEMENT**

The data presented in this study are deposited in the GEO repository, accession number GSE186927.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.

**AUTHOR CONTRIBUTIONS**

Conceptualization, CG and CT. Data Curation, CG and SG. Formal Analysis, CG, AA, NK, SG, MD, and FL. Funding Acquisition, CG and CT. Investigation, CG, AA, and SG. Methodology, CG, SG, MD, HP-W, and CT. Project Administration, CG, SG, and CT. Resources, HP-W, AM, and CT. Software, FL and NN. Supervision, CT. Validation, CG, AA, NK, NN, and CT. Visualization, CG, AA, SG, NK, MD, and FL. Writing – Original Draft, CG, AA, NK, IJ, and CT. Writing – Review and Editing, CG, IJ, and CT. All authors contributed to the article and approved the submitted version.

**FUNDING**

CT was supported by funding from the National Institutes of Health (NIH) under award number R01CA227517-01A1 and GI SPORE grant (P50CA221707), by the Cancer Prevention & Research Institute of Texas (CPRIT) under grant RR140012, by the V Foundation (V2015-22), by the Sidney Kimmel Foundation, by a Sabin Family Foundation Fellowship, by the Reaumond Family Foundation, by the Childress Family Foundation, by the McNair Family Foundation, and by generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program. CG was supported by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) of the NIH under award number F31DK121384. MD was supported by the National Cancer Institute (NCI) of the NIH under award number F31CA210631. CG, MD, AA, and IS were also supported by the NIH/NCI under award number U54CA096300/297. This work was also supported in part by NIH/NIDDK grant DK056338, which supports the Texas Medical Center Digestive Diseases Center, and by NIH/NCI Cancer Center Support Grants (CCSG) P30CA016672, which supports MDACC’s Sequencing and Microarray Facility.
ACKNOWLEDGMENTS

We thank all the members and alumni of the Taniguchi Lab for input throughout the course of this study. Experimental design figures were made using BioRender.com.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.769385/full#supplementary-material

Supplementary Table 1 | Primer Assays used for qRT-PCR.

Supplementary Table 2 | Differentially Expressed Genes in HIF2-overexpressing duodenal organoids versus wild-type duodenal organoids.

Supplementary Table 3 | Differentially Expressed Genes in HIF1-overexpressing duodenal organoids versus wild-type duodenal organoids.

Supplemental Figure 1 | Differentially expressed gene profile in HIF1- overexpressing duodenal organoids. (A) Heatmap shows all the differentially expressed genes in duodenal organoids infected with Adeno-hHIF1 or control Adeno-GFP evaluated via RNA sequencing (n = 3 biological replicates/group). (B) Volcano plot of the differentially expressed genes.

Supplementary Figure 2 | Sequences of the Human WNT5A promoter WT and HRE mutant constructs used for this study.

Supplementary Figure 3 | Wnt5a does not a mitigate radiation-induced intestinal crypt cell death. (A) CBRLuc-mCherry duodenal reporter organoids treated with vehicle (PBS) or 1 μg/ml Wnt5a for 10h were exposed to the indicated doses of ionizing radiation, and then were treated with wnt5a again immediately after the spheroid formation assay was seeded, and 48h later. Bioluminescence was measured 6 days post-radiation (n = 3 per group). Continuous Wnt5a treatment does not improve clonogenic capacity of CBRLuc-mCherry organoids exposed to radiation. (B) CBRLuc-mCherry duodenal reporter organoids were exposed to the indicated doses of ionizing radiation, and then were treated with vehicle (PBS) or 1 μg/ml Wnt5a for 5h and 48h after irradiation. Bioluminescence was measured 6 days post-radiation (n = 3 per group). Post-radiation Wnt5a treatment does not improve clonogenic capacity of CBRLuc-mCherry organoids. All error bars represent mean ± SEM. *P < 0.05, by Student’s t test.

Supplementary Figure 4 | Wnt5a is necessary for crypt regeneration in response to radiation. Wnt5afl/fl duodenal organoids infected with Adeno-Cre-GFP or Adeno-GFP and were then exposed to the indicated doses of ionizing radiation. Z-stack images were stitched and organoids larger than 150 μm in diameter were quantified 6 days post-radiation (see Figure 5E for mean surviving fraction values; n = 3 per group). Representative bright field Z-stack images are shown.

REFERENCES

1. Begg AC, Stewart FA, Vens C. Strategies to Improve Radiotherapy With Targeted Drugs. Nat Rev Cancer (2011) 11(4):239–53. doi: 10.1038/nrc3007
2. Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, et al. Duodenal Toxicity After Fractionated Chemoradiation for Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys (2013) 85(3):e143–e9. doi: 10.1016/j.ijrobp.2012.09.035
3. Elhammali A, Patel M, Weinberg R, Verma V, Liu J, Olsen JR, et al. Late Gastrointestinal Tissue Effects After Hypofractionated Radiation Therapy of the Pancreas. Radiat Oncol (2015) 10(1):186. doi: 10.1186/s13014-015-0489-2
4. Lee KJ, Yoon HI, Chung MJ, Park JY, Bang S, Park S, et al. A Comparison of Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. J Chest Surg (2016) 10(2):303–9. doi: 10.5009/gnl15186
5. Raturi VP, Tochinai T, Hojo H, Rachi T, Hotta K, Nakamura N, et al. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys (2016) 94(4):755–65. doi: 10.1016/j.ijrobp.2015.12.003
6. Kelloh AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology–RTOG 1203. J Clin Oncol (2018) 36(24):2538–44. doi: 10.1200/JCO.2017.77.4273
7. Krishnan S, Chalha AS, Shu Y, Chen H-C, Rao A, Das P, et al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemotherapy. Int J Radiat Oncol Biol Phys (2016) 94(4):755–65. doi: 10.1016/j.ijrobp.2015.12.003
8. Kim SK, Wu C-C, Horowitz DP. Stereotactic Body Radiotherapy for the Pancreas: A Critical Review for the Medical Oncologist. J Gastrointest Oncol (2016) 7(3):479–86. doi: 10.21037/jgo.2015.10.01
9. Hofte S, Frakes JM, Aguilera TA, Czito B, Palla M, Brookes M, et al. Randomized, Double-Blinded, Placebo-Controlled Multicenter Adaptive Phase I–2 Trial of GC 4419, a Dismutase Mimetic, in Combination With High-Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (Pc). Int J Radiat Oncol Biol Phys (2020) 108(5):1399–400. doi: 10.1016/j.ijrobp.2020.09.022
10. Yan KS, Chia LA, Li X, Ootani A, Su J, Lee JY, et al. The Intestinal Stem Cell Markers Bmi1 and Lgr5 Identify Two Functionally Distinct Populations. Proc Natl Acad Sci (2012) 109(2):466. doi: 10.1073/pnas.1118557109
11. Taylor CT, Colgan SP. Hypoxia and Gastrointestinal Disease. J Mol Med (2005) 83(12):1295–300. doi: 10.1007/s00109-007-0277-z
12. Kaelin WG, Ratcliffe PJ. Oxygen Sensing by Metazoa: The Central Role of the HIF Hydroxylase Pathway. Mol Cell (2008) 30(4):393–402. doi: 10.1016/j.molcel.2008.04.009
13. Keith B, Simon MC. Hypoxia-Inducible Factors, Stem Cells, and Cancer. Cell (2007) 129(3):465–72. doi: 10.1016/j.cell.2007.04.019
14. Ivan M, Kondo K, Yang H, Kim W, Valandi J, Ohh M, et al. Hirf Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing. Science (2001) 292(5516):464. doi: 10.1126/science.1059817
15. Jaakkola P, Mole DR, Gielbert J, Gaskell SJ, et al. Targeting of HIF-α to the Von Hippel-Lindau Ubiquitinylation Complex by O2-Regulated Prolyl Hydrolases. Science (2001) 292(5516):468. doi: 10.1126/science.1059796
16. Yu F, White SB, Zhao Q, Lee FS. HIF-1α Binding to VHL is Regulated by Stimulus-Sensitive Proline Hydroxylation. Proc Natl Acad Sci (2001) 98(17):9630. doi: 10.1073/pnas.181341498
17. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent Function of Two Destruction Domains in Hypoxia-Inducible Factor-α Chains Activated by Prolyl Hydroxylation. EMBO J (2001) 20(18):5197–206. doi: 10.1093/emboj/20.18.5197
18. Epstein AGR, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, et al. C. Elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases That Regulate HIF by Prolyl Hydroxylation. Cell (2001) 107(1):43–54. doi: 10.1016/S0092-8674(01)00507-4
19. Bruick RK, McKnight SL. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF. Science (2001) 294(5545):1337. doi: 10.1126/science.1066373
20. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-Mediated Stimulation of Carcinoma Cell Invasiveness via Upregulation of Urokinase Receptor Expression. Int J Cancer (1999) 80(4):817–23. doi: 10.1002/(SICI)1097-0215(19990209)80:4<817::AID-IJC23>3.0.CO;2-C
21. Synnestvedt K, Furtuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. ECO-3'-Nucleotidase (CD73) Regulation by Hypoxia-Inducible Factor-1 Mediates Permeability Changes In Intestinal Epithelia. J Clin Invest (2002) 110(7):993–1002. doi: 10.1172/JCI15337
22. Taniguchi CM, Miao YR, Diep AN, Wu C, Rankin EB, Atwood TF, et al. PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal Toxicity via HIIF. Sci Trans Med (2014) 6(236):236ra64. doi: 10.1126/scitranslmed.3008523
23. Fujiyomi TN, Colbert LE, Huang Y, Molkentine JM, Deorukhkar A, Baseler L, et al. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Res (2019) 79(9):2327. doi: 10.1158/0008-5472.CAN-18-1785
24. Miyoshi H, Stappenbeck TS. In Vitro Expansion and Genetic Modification of Gastrointestinal Stem Cells in Spheroi...